About this website

This website supports the running of clinical trials for human medicines in the European Union (EU) and European Economic Area (EEA).

Use of Clinical Trials Information System becomes mandatory for new clinical trial applications in the EU

From 31 January 2023, all initial clinical trial applications in the European Union (EU) must be submitted via the Clinical Trials Information System (CTIS). CTIS is now the single-entry point for sponsors and regulators of clinical trials for the submission and assessment of clinical trial data. This follows a one-year transition, during which sponsors could choose whether to apply for a new clinical trial in the EU/EEA in line with the Clinical Trials Directive or under the new Clinical Trials Regulation (CTR), which entered into application on 31 January 2022.

In the past, sponsors had to submit clinical trial applications separately to national competent authorities (NCAs) and ethics committees in each country to gain regulatory approval to run a clinical trial. Registration and the posting of results were also separate processes. With CTIS, sponsors can now apply for authorisations in up to 30 EU/EEA countries at the same time and with the same documentation. The system includes a public, searchable database for healthcare professionals, patients, and other interested parties.

The CTR foresees a three-year transition period, from 2022 to 2025. The first milestone has been reached today; in the next two years, by 31 January 2025, all ongoing trials that were approved under the Clinical Trials Directive will be governed by the new Regulation and will have to be transitioned to CTIS.

The application of the CTR strengthens Europe as an attractive location for clinical research. The new regulation streamlines the processes for the application and supervision of clinical trials, and their public registration: all clinical trial sponsors will now use the same system and follow the same procedures to apply for the authorisation of a clinical trial, no matter where they are located and which National Competent Authority (NCA) or national ethics committee they are dealing with.

The authorisation and oversight of clinical trials is the responsibility of EU/EEA Member States while the European Medicines Agency (EMA) is responsible for maintaining CTIS. The European Commission (EC) oversees the implementation of the Clinical Trials Regulation.



Notes

  • This press release, together with all related documents, is available on the Agency's website.
  • More information on the work of the European Medicines Agency can be found on its website: European Medicines Agency

Introduction

A clinical trial is a study performed to investigate the safety or efficacy of a medicine. For medicines intended for human use, these studies are carried out in people who volunteer.

Clinical trials in the EU and EEA are governed by the Clinical Trials Regulation (Regulation (EU) No 536/2014) which came into application on 31 January 2022. It is part of a broad initiative to transform the EU/EEA clinical trials environment in support of large clinical trials in multiple European countries, to the benefit of medical innovation and patients.

The regulation of clinical trials aims to ensure that the rights, safety and well-being of clinical trial participants are protected and the results of clinical trials are reliable and informative.

  • Clinical trial sponsors (usually researchers or companies that oversee a clinical trial and collect and analyse the data) can use this website to apply for permission to run a clinical trial anywhere in the EU/EEA including in multiple countries, provide updates to national regulators about a trial, and submit trial results.
  • EU/EEA national regulators can use it to process clinical trial applications collaboratively, request further information, authorise or refuse a trial and oversee an authorised trial.
  • Anybody can use it to view information on clinical trials in the EU and EEA from 31 January 2022.

Clinical trial sponsors and EU/EEA national regulators work in the Clinical Trials Information System, the system underpinning this website.

The EU Member States and EEA countries, the European Commission and EMA launched the Clinical Trials Information System on 31 January 2022. On the same day, EMA launched this website. EMA maintains this website in collaboration with the EU Member States and EEA countries, and the European Commission.

CTIS is a registered data provider for the World Health Organization (WHO). Data from authorised trials published on this website, excluding those with category 1 deferrals of the main characteristics, is included in the search portal of WHO's International Clinical Trials Registry Platform (ICTRP). This applies to relevant clinical trial data, as required by WHO, which has been published on CTIS since the launch of the system on 31 January 2022.

Publicly accessible registries that are data providers to WHO's ICTRP are accepted by the International Committee of Medical Journal Editors (ICMJE), according to its recommendations.

For more information on the regulation of clinical trials in human medicines, see:

Secure workspaces

This website supports the business processes of clinical trial sponsors and national regulators throughout the lifecycle of a clinical trial, via the secure Sponsor workspace and Authority workspace Users need to log into these secure workspaces.

Clinical trial sponsors can apply for authorisation to run a clinical trial in up to 30 EEA countries via a single application in this website. They can also carry out tasks including liaising with national regulators while a trial is ongoing and recording the results of the trial.

National regulators can work together using this website on the assessment and authorisation of a clinical trial in several countries.

They can also use this website together with other systems to work together on clinical trial oversight, including monitoring and assessing safety-related data in the context of a clinical trial.

CTIS for sponsors

Clinical trial sponsors and other organisations involved in running clinical trials can apply to run a trial and can manage an ongoing trial in up to 30 countries in the European Union and European Economic Area via the Clinical Trials Information System (CTIS).

CTIS for authorities

Regulatory authorities, such as national competent authorities and ethics committees of EU Member States and European Economic Area countries can participate in the assessment, authorisation or oversight of a trial.

Searching for clinical trials

This website contains limited information on individual clinical trials entered since its launch on 31 January 2022.

It will gradually contain more information as clinical trial sponsors and EU/EEA regulators use it to initiate and oversee clinical trials in the EU and EEA.

For information on individual clinical trials initiated before 31 January 2022 see:

European Union Clinical Trials Register

To find detailed information on clinical trials granted or refused permission in the EU and EEA via the Clinical Trial Information System, this website has a search function.

You can view information on individual clinical trials as soon as it becomes available, such as the EU clinical trial number, name and address of the trial sponsor, start and end dates of participant recruitment and of the trial itself.

Further information, including the identity of the investigational medicine and details of the trial design, is also made available via this website, but its publication may be deferred to protect legitimate economic interests.

Training and support

Training and supporting materials are available from EMA on how to use the Clinical Trials Information System, and a dedicated user support service is available:

The Clinical Trials Information System, the system underpinning this website, serves to implement EU pharmaceutical law in the Clinical Trials Regulation (Regulation (EU) No 536/2014). The goal of the Regulation is to create a favourable environment for conducting clinical trials in the EU, to ensure the EU remains an attractive region for clinical research, with the highest standards of safety for participants and transparency of information.

It does this by harmonising the submission, assessment and supervision processes for clinical trials supported by this website. Before the launch of this website, sponsors had to submit clinical trial applications separately to national competent authorities and ethics committees in each country to gain regulatory approval to run a clinical trial.

The EU Member States and EEA countries, the European Commission and EMA launched the Clinical Trials Information System on 31 January 2022. On the same day, EMA launched this website. EMA maintains this website in collaboration with the EU Member States and EEA countries, and the European Commission.

The assessment, authorisation and supervision of clinical trials are the responsibilities of EU Member States and EEA countries.

Transition period

Under the Clinical Trials Regulation, EU Member States and EEA countries will carry out their legal responsibilities to assess and oversee clinical trials using the Clinical Trials Information System from its launch on 31 January 2022.

  • Clinical trial sponsors can choose whether to apply to start a clinical trial via the Clinical Trials Information System or under the Clinical Trials Directive until 30 January 2023.
  • From 31 January 2023 onwards, clinical trial sponsors will need to apply to start a clinical trial via the Clinical Trials Information System.
  • By 31 January 2025, any ongoing trials approved under the Clinical Trials Directive will fall under the Regulation and information about them will need to be transferred to the Clinical Trials Information System.

For more information:

EMA news and events

Find EMA news and events related to clinical trials in the EU and the EEA.